Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial

travellinglight/iStock via Getty Images Biogen (NASDAQ:BIIB) and Japanese drugmaker Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced their experimental Alzheimer’s medication lecanemab met the main goal in a large-stage trial, sparking pre-market gains Wednesday…

This News Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial appeared first on STL.News.